Weight Maintenance After GLP-1: What the 2026 Data Actually Shows

Weight regain after stopping GLP-1 medication has been the biggest concern for patients and providers alike. The 2026 data provides the most nuanced picture yet — and it's more encouraging than the early "you'll gain it all back" narrative suggested.

SURMOUNT-MAINTAIN (Lancet 2026)

This trial followed patients who had lost significant weight on tirzepatide and randomized them to three groups at week 88: continue maximum dose, step down to 5mg, or switch to placebo.

Orforglipron Maintenance Data

IAPAM reported that 43.7% of patients who switched from tirzepatide to orforglipron and 55% of those who switched from semaglutide to orforglipron maintained at least 80% of their prior weight loss. This suggests that switching from injectable to oral GLP-1 is a viable maintenance strategy.

What the Data Tells Us

Continuing works best: Patients who stay on medication at their effective dose maintain the most weight loss. This is consistent with treating obesity as a chronic condition requiring ongoing management.

Stepping down works well: Reducing to a lower dose maintained roughly 75% of the maximum-dose weight loss. This is the emerging standard of care — reach your goal, stabilize, then step down to the lowest effective maintenance dose.

Stopping still retains some benefit: Even patients on placebo kept nearly 10% weight loss at follow-up — suggesting that lifestyle changes made during treatment have lasting effects.

Switching formats works: Moving from injectable to oral GLP-1 for maintenance appears viable, preserving most weight loss while improving convenience and potentially reducing cost.